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https://doi.org/10.1016/j.molcel.2020.06.013SUMMARYProtein secretion in eukaryotes and prokaryotes involves a universally conserved protein translocation chan-
nel formed by the Sec61 complex. Unrelated small-molecule natural products and synthetic compounds
inhibit Sec61 with differential effects for different substrates or for Sec61 from different organisms, making
this a promising target for therapeutic intervention. To understand the mode of inhibition and provide insight
into the molecular mechanism of this dynamic translocon, we determined the structure of mammalian Sec61
inhibited by the Mycobacterium ulcerans exotoxin mycolactone via electron cryo-microscopy. Unexpect-
edly, the conformation of inhibited Sec61 is optimal for substrate engagement, with mycolactone wedging
open the cytosolic side of the lateral gate. The inability of mycolactone-inhibited Sec61 to effectively trans-
port substrate proteins implies that signal peptides and transmembrane domains pass through the site occu-
pied bymycolactone. This provides a foundation for understanding themolecularmechanism of Sec61 inhib-
itors and reveals novel features of translocon function and dynamics.INTRODUCTION
Biogenesis of eukaryotic secretory or transmembrane proteins
often occurs at the surface of the endoplasmic reticulum through
the process of co-translational translocation. Here proteins tar-
geted to the membrane by a signal sequence are translocated
during translation through a membrane-spanning protein conduit
formed by the Sec61abg complex. An analogous system, Se-
cYEG, is found in the plasma membrane of bacteria, where it
also mediates protein secretion. The structure of the heterotri-
meric Sec complex is conserved throughout evolution and con-
tains the core channel-forming subunit Sec61a/SecY together
with the smaller subunits Sec61b/SecG and Sec61g/SecE (Van
den Berg et al., 2004; Voorhees et al., 2014). The translocon forms
a gated channel that maintains membrane integrity while selec-
tively opening to allow passage of the unfolded polypeptide chain.
In addition, the translocon must open laterally to allow the trans-
membrane helices of membrane proteins to pass into the mem-
brane environment as they are translated.
Structural studies of the translocon have provided snapshots of
how thisdynamic complex operates. Sec61a/SecY is formed from
10 transmembranehelices thatarearranged ina ‘‘clamshell’’ archi-
tecture (Van denBerg et al., 2004). In the resting state, this forms a406 Molecular Cell 79, 406–415, August 6, 2020 ª 2020 The Author(s
This is an open access article under the CC BY license (http://creativetransmembrane channel, which is occluded by a central constric-
tion of hydrophobic residues, known as the pore ring, and a short
plughelix,whichblocks the lumenal exit. A secondpotential open-
ing, the lateral gate, liesat the interfacebetweenhelicesH2/H3and
H7/H8. This gate is stabilized by a polar cluster and is proposed to
open toprovidea route for translocating transmembranehelices to
pass into themembrane (Van denBerg et al., 2004). Duringprotein
translocation, the plug helix is displaced to open the channel,
whereas the dynamic opening and closing of the lateral gate is
thought to allow regions of the elongating polypeptide to partition
into the endoplasmic reticulum lumen or the membrane environ-
ment, depending on their hydrophobicity.
More recently, cryoelectron microscopy studies have allowed
visualization of ribosome-translocon complexes in different
stages of translocation. These show that ribosome binding
primes the translocon, loosening the lateral gate and breaking
the polar cluster (Voorhees et al., 2014). During co-translational
translocation, the N-terminal signal peptide interacts with a hy-
drophobic patch of residues near the lateral gate, occupying
the position previously taken by helix H2 of Sec61a (Voorhees
and Hegde, 2016a). In this state, the plug helix is displaced,
opening the channel for translocation. The translocon can also
operate post-translationally, with the allosteric activators). Published by Elsevier Inc.
commons.org/licenses/by/4.0/).
Figure 1. The Structure of the Sec61 Translocon Inhibited by Mycolactone
(A) The structure of mycolactone A/B (743 Da). The 12-membered lactone core is indicated, as are the two polyketide side chains, commonly referred to as the
northern and southern chains. Mycolactone A/B is a 3:2 rapidly equilibrating mixture of Z-D40,50 and E-D40,50 geometric isomers at the second double bond in the
southern fatty acid tail.
(B) Mycolactone concentrations in purified ribosome-translocon complexes extracted from membranes treated (+) or not treated () with mycolactone,
determined by high-resolution LC-MS with the extracted ion chromatogram peaks integrated to obtain the [mycolactone+Na]+ (m/z 765.4721–765.5103) ion
eluting at 2.38–2.98 relative to the calibration curve.
(C) Electron density for Sec61a in the presence of mycolactone. Electron density maps were low-pass-filtered to 5 A˚; the density feature corresponding to
mycolactone is colored pink. The insets show two close-up views centered on the mycolactone density.
(D) The structure of the Sec translocon with Sec61a colored, with helices H1–H5 in blue, H6–H10 in red, Sec61b in green, and Sec61g in orange. Mycolactone is
shown as spheres, with carbon in white and oxygen in red.
See also Figures S1–S5.
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Sec61a in which the cytoplasmic side of the lateral gate is
open (Itskanov and Park, 2019; Wu et al., 2019) but the plug helix
remains in place (Wu et al., 2019). This prepares the translocon to
bind and be gated by weak signal peptides.
These studies reveal that the translocon is dynamic, with struc-
tural transitionsmodulated by associations with the signal peptide
(Gouridis et al., 2009) or allosteric activators (Itskanov and Park,
2019; Wu et al., 2019). Open states are stabilized by binding part-
ners that hold helices H2 and H3 in a conformation in which the
lateral gate is open and the plug helix is displaced (Gemmer and
Fo¨rster, 2020; Lang et al., 2017; Rapoport et al., 2017; Voorhees
and Hegde, 2016b). There are also a number of inhibitors that act
on Sec61a but no detailed molecular insight into how they modu-
late the structure or conformational dynamics of the translocon.
Two studies showed that selective inhibitors of protein secre-
tion can block co-translational translocation by acting directly
on Sec61 (Besemer et al., 2005; Garrison et al., 2005). Inhibitors
of Sec61-dependent translocation that act in this way includemy-
colactone, apratoxin A, cotransin, and ipomoeassin F (Cross et al.,
2009; Hall et al., 2014; Haßdenteufel et al., 2018; Junne et al.,2015; Mackinnon et al., 2014; Paatero et al., 2016; Zong et al.,
2019). These molecules have diverse structures but compete
when binding to Sec61a, suggesting that they bind to overlapping
sites (Baron et al., 2016; Paatero et al., 2016; Zong et al., 2019).
Indeed,mutations of Sec61a that cause resistance to one inhibitor
often also cause resistance to the others, suggesting a shared
mode of action. Despite this, different inhibitors show variable
specificity for translocons from different species and block trans-
location of different classes of substrates, raising the possibility of
developing therapeutically useful selective translocon modula-
tors. Of the current inhibitors, mycolactone (Figure 1A) is the
most potent (Hall et al., 2014). This diffusible lipid-like exotoxin
is synthesized by the Buruli ulcer pathogenMycobacterium ulcer-
ans (Demangel andHigh, 2018; Yotsu et al., 2018) and forms a sta-
ble complexwith Sec61a (Baron et al., 2016). It prevents co-trans-
lational translocation of secretory proteins, including inflammatory
mediators and cytokines, at nanomolar concentrations (Baron
et al., 2016; Hall et al., 2014; McKenna et al., 2016) and blocks
Sec61-dependent insertion of many transmembrane proteins
(Baron et al., 2016; McKenna et al., 2017). Mycolactone inhibits
translocation at a stage after ribosome engagement with theMolecular Cell 79, 406–415, August 6, 2020 407
Table 1. Refinement and Model Statistics
-
Ribosome:
Sec61 +
Mycolactone
Ribosome:
Sec61
Data Collection and Processing
Magnification 165,000 165,000
Voltage (kV) 300 300
Electron exposure (e/A˚2) 49 49
Defocus range (mm) 1.0 to 2.5 1.0 to 2.5
Pixel size (A˚) 0.822 0.822
Symmetry imposed C1 C1
Initial particle images (no.) 108,129 49,733
Final particle images (no.) 45,733 24,852
Map resolution (A˚) 2.63 2.85
Fourier Shell Correlation threshold 0.143 0.143
Refinement
Map pixel size (A˚) 1.033
Map sharpening B factor (A˚2) 5.7
Map lowpass filter (A˚) 4.0
Model resolution (A˚) 4.0
Model Composition
Non-hydrogen atoms 3,608
Protein residues 441
Ligands MYC: 1
Average B Factors (A˚2)
Protein 65.98
Ligands 71.85
Root-Mean-Square Deviations (RMSDs)
Bond lengths (A˚) 0.006
Bond angles () 1.047
Validation
MolProbity score 1.79
Clashscore 5.40
Poor rotamers (%) 0.53
Ramachandran Plot
Favored (%) 91.61
Allowed (%) 8.39
Disallowed (%) 0.00
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(McKenna et al., 2016). The availability of this potent and stably
bound inhibitor provided us with the opportunity to visualize the
translocon trapped in the inhibited state.RESULTS
Cryoelectron Microscopy of Mycolactone-Inhibited
Ribosome-Translocon Complexes
Although there is, to date, no high-resolution crystal structure of a
eukaryotic Sec61 homolog, cryoelectron microscopy of ribo-
some-translocon complexes has allowed visualization of translo-
conswith different binding partners or captured in different states.408 Molecular Cell 79, 406–415, August 6, 2020We therefore purified ribosome-translocon complexes (RTCs)
from canine microsomal membranes that had been incubated
with mycolactone at a concentration that completely prevented
prepro-a factor translocation (Figure S1). Liquid chromatog-
raphy-mass spectrometry (LC-MS) was used to confirm the pres-
ence ofmycolactone in these complexes (Figure 1B; Figure S2). In
addition, to ensure that the observed changes were due to the
presence of mycolactone rather than due to details of our prepa-
ration or imaging protocols, we prepared a control sample of ribo-
some-translocon complexes in the absence of inhibitor.
We next prepared grids to allow visualization of these samples
by cryoelectron microscopy. Although samples prepared in stan-
dard holey grids or grids overlaid with a 2-nm layer of carbon
showed preferred orientations, complexes vitrified on graphene
oxide-coated grids allowed imaging ofmultiple views and genera-
tionof three-dimensional reconstructions (FiguresS3–S5;Table1).
Ribosomes were predominantly translocon bound, and particle
subtraction and focused classification on mycolactone-bound
translocons yielded a map with an overall resolution of 2.6 A˚ and
local resolutions for Sec61a from 2.4–8.7 A˚ (Figure 1; Figure S3).
The resolution is highest for the C-terminal ribosome-bound half
of Sec61a (H6–H10), whereas the N-terminal half (H1–H5) is
more dynamic and less clearly defined (Figure S3). A model was
built containing all transmembrane helices of Sec61a, themajority
ofSec61g, andapoly-alaninehelix forSec61b. Thecontroldataset
generated an electron densitymap at an overall resolution of 2.8 A˚
in which the positions of the helices were essentially indistinguish-
able from the previously reported structure of a primed translocon
(Voorhees et al., 2014), indicating that the changes observed in the
mycolactone-bound translocon were due to the presence of my-
colactone (Figures S5). An elongated density within the cytosolic
sideof the lateral gateof the transloconwas theonlydifferencebe-
tween mycolactone-bound and mycolactone-free translocons
that was not due to helix movement and was attributed to myco-
lactone (Figure 1C). A comparisonofmycolactone-bound andmy-
colactone-free ribosome-translocon complexes revealed no dif-
ferences in the conformation of the ribosome, the occupancy of
tRNA-binding sites, or the presence of associated proteins
because of the presence of mycolactone (Figures S1 and S3–
S5), supporting the finding that mycolactone does not directly
affect translation elongation (Hall et al., 2014).
Mycolactone Stabilizes a Partially Activated
Conformation of Sec61
A comparison of the conformations of the mycolactone-bound
and mycolactone-free translocons (Voorhees et al., 2014) identi-
fied no differences in the ribosome-bound C-terminal half of
Sec61a. However, in the presence of mycolactone, a major
structural changewas observedwithin themore flexible N-termi-
nal half, with an 9-A˚ movement of the cytoplasmic ends of he-
lices H2 and H3 and smaller tilting of helix H4. This movement of
H2 and H3 away from H7 and H8 results in opening of the cyto-
plasmic side of the lateral gate (Figure 2). Toward the lumenal
side of the translocon lies the plug helix. This plug is present in
the primed conformation of the translocon (Voorhees et al.,
2014) but is displaced in the signal peptide-bound conformation,
opening the channel (Voorhees and Hegde, 2016a). In the pres-
ence of mycolactone, the plug helix is clearly visible in the
Figure 2. The Mycolactone-Stabilized Conformation of the Sec Translocon
Structural overlays of the mycolactone-bound conformation of Sec61a, with helices H1–H5 in blue and helices H6–H10 in red. This has been overlaid with the
primed conformation (top panel; PDB: 3J7Q), the open signal peptide-bound conformation (center; PDB: 3JC2), and the Sec62/63-bound conformation (bottom;
PDB: 6ND1), all in white. The left panel shows the helices as cylinders. The center panel shows helices H2, H3, H7, and H8 in cartoon representation, with the
lateral gate shown as a dotted line. The right panel shows a close up centered on the plug helix (P).
ll
OPEN ACCESSArticleelectron density maps, retaining its a-helical character but
showing a displacement of 7 A˚ from its location in the primed
state. However, this displacement is not sufficient to allow chan-
nel opening, with the plug helix still occluding the channel
(Figure 2).
Comparison of the structure of the mycolactone-bound translo-
con with those of eukaryotic primed (Voorhees et al., 2014), signal
peptide-bound (Voorhees and Hegde, 2016a), and Sec62/63-
bound states (Itskanov andPark, 2019;Wuet al., 2019; Figure 2) re-
veals mycolactone to stabilize a conformation of Sec61a most
similar to that observed in the presence of a complex of Sec62
and Sec63. This conformation of Sec61a is associated with post-
translational translocation, in which the translocon is poised to
accept substrates and to be gated by inefficient signal peptides.
Indeed, stabilization of this state by Sec62/63 is thought to facilitate
translocation,making it surprising that this is thestatestabilizedbya
translocation inhibitor.
A Proposed Binding Site for Mycolactone at the
Cytoplasmic Entrance of the Channel
Comparison of the electron density maps for mycolactone-
bound and mycolactone-free translocons (Voorhees et al.,2014) reveals a single density feature that was not attributed to
helix movement (Figure 1C). Because mycolactone must be pre-
sent in the translocon to account for stabilization of this confor-
mation, we docked mycolactone into this density. This binding
pocket lies between helices H2 and H8 of Sec61a, within a hy-
drophobic groove created by opening of the lumenal side of
the lateral gate (Figure 3A). Residues that line this groove and
contact mycolactone include hydrophobic side chains that
form part of the pore ring (V85 and I179) and hydrophobic patch
(L89 and I179) of Sec61a and are thought to play important roles
in channel closure and signal peptide binding (Figures 3B and
3C). The electron density attributed to mycolactone consists of
a wider central region into which we docked the lactone core
of mycolactone. On either side of this are two narrower regions
of density likely to correspond to the polyketide side chains.
These are not sufficiently well defined to precisely place myco-
lactone because of the 5-A˚ resolution of this region of the
map (Figure S3) coupled with the potential for mycolactone
isomerization (George et al., 1999) and the inherent flexibility of
its polyketide chains.
To further assess the pose of mycolactone within this binding
site and to determine whether it remains stably bound duringMolecular Cell 79, 406–415, August 6, 2020 409
Figure 3. The Mycolactone Binding Site and the Location of Resi-
dues Whose Mutation Leads to Mycolactone Resistance
(A) Structure of Sec61a, with helices H1–H5 in blue and H6–H10 in red. The
electron density for mycolactone is shown as a white surface.
(B) A close up of the mycolactone binding site, highlighting hydrophobic res-
idues that lie in this pocket.
(C) A second view of the mycolactone binding site from the cytoplasmic face,
viewed approximately perpendicular to the membrane.
(D) A view of the primed conformation of Sec61a, viewed from the same di-
rection as in (C).
(E and F) Two views of the outcome of molecular dynamics simulations in
which mycolactone was allowed to move within a restrained translocon. The
original position of mycolactone, determined by fitting into the electron den-
sity, is shown as orange sticks, whereas gray sticks show variation in the
position of mycolactone through a 100-ns trajectory, and yellow sticks show
the position of mycolactone at the end of the trajectory. The electron density
for mycolactone is shown as a white surface.
See also Figure S6.
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OPEN ACCESS Articlesimulation, we usedmolecular dynamics (Figures 3E and 3F; Fig-
ure S6). Two possible orientations ofmycolactone could fit within
the electron density, with the longer southern chain protruding
into the hydrophobic environment of the lipid bilayer or into the
core of the translocon. To assess the likelihood of each possible
orientation, we modeled the E-D40,50 isomer of mycolactone, the
presumptive active form (Gehringer et al., 2019), into this density
in either possible orientation, and molecular dynamics simula-
tions were conducted to assess their stability. In both cases, my-
colactone remained stably bound over the 100-ns time course of
the simulation. However, the conformation in which the southern410 Molecular Cell 79, 406–415, August 6, 2020chain protrudes into the lipid bilayer showed less variation during
the simulation and was better accommodated within the binding
pocket as well as within the electron density, suggesting this to
be the most likely binding mode. Here the lactone core forms
the majority of the interaction with the translocon, with the north-
ern chain also interacting, whereas the long southern chain is
predominantly flexible and disordered.
Mycolactone Resistance Mutations Reduce
Mycolactone Binding, Most Likely by Modulating
Translocon Dynamics
The structure of the mycolactone-bound translocon allowed us
to revisit how Sec61a mutations cause resistance to inhibitors.
A number of studies have identified mutations that overcome
the cytotoxic effects of mycolactone. Indeed, the same muta-
tions often affect multiple different inhibitors, supporting the
idea of a common binding mode (Baron et al., 2016; Junne
et al., 2015;Mackinnon et al., 2014; Ogbechi et al., 2018; Paatero
et al., 2016; Zong et al., 2019). We now conducted an additional
forward genetic screen that identified nine substitutions in six co-
dons that gave mycolactone resistance, five of which overlap-
ped with those identified previously (Figure 4A; Figure S7; Tables
S1 and S2). Although not identified in our screen, mutation of T86
is also reported to confer resistance to mycolactone (Zong et al.,
2019). Unexpectedly, of the residues associated with resistance
mutations, only T86 directly contacts mycolactone. Instead, the
majority lie on or around the plug helix, on the lumenal side of the
translocon, away from the mycolactone-binding pocket (Fig-
ure 4B). Indeed, no extra electron density is observed in the my-
colactone-bound translocon, which directly contacts residues
associated with resistance mutations.
Although we cannot be sure why resistance mutations were
not found in the binding pocket, this may be due to the essential
role of residues that contact mycolactone. These include hydro-
phobic residues that play functionally important roles in the
structure and dynamics of Sec61a, including roles in the pore
ring (V85 and I179) and the hydrophobic patch (L89 and I179).
It is therefore possible that mutations in these residues that
cause sufficiently large changes in side-chain chemistry to
reducemycolactone binding alsomake the translocon non-func-
tional, precluding their appearance in a forward genetic screen.
Indeed, the naturally occurring mutation V85D, found in hypo-
gammaglobulinemia, is defective in co-translational transloca-
tion (Schubert et al., 2018).
With the surprising finding that resistance mutations are not
found in residues that contact mycolactone, we used LC-MS
and molecular dynamics to assess whether these mutations
affect binding of mycolactone to the translocon. To directly mea-
sure mycolactone binding, we prepared microsomes from unal-
tered TRex-293 cells as well as from cells stably overexpressing
Sec61a with resistance mutations at positions S71, G80, and
S82. RTCs were prepared in the presence of mycolactone, and
LC-MS was used to quantify mycolactone in these complexes.
In wild-type cells, we estimate that each translocon bound an
average of 0.87 ± 0.04mycolactonemolecules.When performed
with cells overexpressing mutant Sec61a variants, in each case,
the average number of mycolactone molecules per translocon
decreased, with reductions of 70%–80% when normalization
Figure 4. The Location of Mycolactone Resistance Mutations and Their Effect on Mycolactone Binding
(A) Parental HCT-116 cells and representative clones with different amino acid substitutions were tested for their sensitivity to mycolactone A/B. Data are ex-
pressed as a normalized viability index of cells treated with inhibitor for 5 days, after which metabolic activity was assessed with Resazurin dye (alamarBlue
assay), and values were normalized to a DMSO control. The IC50 of wild-type cells for mycolactone A/B was 1.94 nM (1.44 ng/mL). Data are mean ± SEM of n = 3.
(B) A representation of the Sec translocon with Sec61a colored, with helices H1–H5 in blue and H6–H10 in red, Sec61b in green, and Sec61g in orange. My-
colactone is shown as spheres, with carbon in white and oxygen in red. Residues whose mutation leads to mycolactone resistance are represented as yellow
spheres.
(C and D) Microsomes were prepared from TRex-293 cells or those stably transfected with C-terminal FLAG-tagged mutant Sec61A1 constructs. Mycolactone-
exposed RTCs were prepared, and the peak fractions were subjected to LC-MS.
(C) Immunoblotting of peak fractions. Migration relative to knownmolecular weight markers is shown, as is optical density 260 (OD260). The location of an excised
lane is indicated by a dotted line.
(D) Relative mycolactone abundance in the RTCs was estimated using high-resolution LC-MS by integrating the extracted ion chromatogram peaks for the
[mycolactone+Na]+ (m/z 765.4721–765.5103) ion eluting at 2.38–2.98 relative to a calibration curve. To compare between preparations, the data were stan-
dardized on ribosome concentration (calculated from OD260) or Sec61a abundance (pixel intensity of the immunoblot band). Triplicate analysis from n = 1.
(E) Assessment of the dynamics of mycolactone bound to the translocon during 100-ns simulations for wild-type and mutant translocons. Helices H6–H10 were
restrained, and movement was allowed for mycolactone and the remainder of the translocon. In each case, the root-mean-square deviation from the starting
position is shown at each nanosecond for the southern chain, northern chain, and lactone core. Three independent simulations were conducted, and these plots
show the average.
See also Figures S7–S9 and Tables S1 and S2.
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Figure 5. A Model of the Mode of Action of Mycolactone
In this model, the ribosome-bound primed conformation of the Sec translocon
is hypothesized to be in equilibrium with a second state (the putative inter-
mediate), in which the lateral gate is open while the plug helix blocks the
channel. This is similar in structure to the state stabilized by Sec62/63. My-
colactone can enter this intermediate state and stabilize its conformation while
hindering access to the signal peptide binding site.
ll
OPEN ACCESS Articlewas conducted using a Sec61a immunoblot (Figures 4C and 4D;
Figure S8). Because endogenous Sec61a remains in these prep-
arations, this shows that all three mutations cause major reduc-
tions in the binding of mycolactone to the translocon.
In parallel, we performed molecular dynamics to assess the
stability of mycolactone in the binding pocket. Long simulations
of the entire ribosome-translocon system to observe Sec and
mycolactone conformational dynamics were computationally
prohibitive. However, short MD simulations can successfully
be used to provide an assessment of binding stability (Liu
et al., 2017). Because helices H6–H10 of the translocon were
equivalent in conformation between mycolactone-bound and
-free conformations (Figure 2), we fixed these in position and al-
lowed free movement of mycolactone and helices H1–H5. In
three repeats of a 100-ns simulation, mycolactone remained sta-
bly bound. However, introduction of the S71F, G80W, and S82F
mutations each reduced the stability of mycolactone binding, in
particular of the northern chain (Figure 4E; Figure S9). Together
with MS analysis, these studies show that resistance mutations412 Molecular Cell 79, 406–415, August 6, 2020decrease mycolactone binding despite being in residues that
do not make direct contact with mycolactone.
Therefore, the most probable hypothesis for how resistance
mutations function is that they modulate translocon dynamics,
reducing the likelihood of formation of the mycolactone binding
pocket. To assess this, we measured the change in separation
of three pairs of residues that contact mycolactone, V85-
W379, L89-V382, and L89-W379, during themolecular dynamics
simulations of mycolactone-bound S71F, G80W, and S82F
described above (Figure S9). Intriguingly, each mutation
changed the separation of these residues in different ways.
S82F seems to favor an opening of the lateral gate in the region
of the mycolactone binding pocket, perhaps because of intro-
duction of a bulky side chain in a site buried in the mycolac-
tone-bound conformation. In contrast, G80W favored closing
of the lateral gate. A conclusive analysis would require extensive
simulations of complete RTCs and detailed biochemical ana-
lyses of the mutant translocons. However, our analysis suggests
that favoring the open or closed state relative to the mycolac-
tone-bound state can be associated with resistance. Indeed, a
similar allosteric mechanism has been proposed to explain the
role of the prl phenotypes that allow export of proteins with
defective or absent signal peptides (Junne et al., 2007, 2015;
Smith et al., 2005; Trueman et al., 2012). Most of the residues
in which we identified resistance mutations are also associated
with prl phenotypes (Table S1), supporting the idea that their
effects are the result of changes in translocon dynamics. Our
findings therefore confirm that resistance mutations reduce my-
colactone binding without being in residues that directly contact
the inhibitor and suggest that this is achieved by changes in
conformational dynamics that disfavor the mycolactone-bound
conformation.
DISCUSSION
This study reveals the mode of action of Sec61a inhibitors while
also highlighting unexpected features of the mechanism of the
translocon. First we show that mycolactone wedges open the
cytoplasmic side of the lateral gate of Sec61a. This stabilizes a
conformation very similar to that stabilized by Sec62/63, which
is poised and permissive for post-translational translocation.
Therefore, unexpectedly, mycolactone does not stabilize the
inactive translocon but traps the helices of Sec61a in a partly
activated conformation.
The density attributed to mycolactone lies directly across the
cytoplasmic side of the channel. Although the route the signal
peptide takes during co-translational translocation is not fully
resolved, the location of the engaged signal peptide has been
mapped to a site within the lateral gate in translocating ribo-
some-translocon complexes (Voorhees and Hegde, 2016a).
The locations occupied by mycolactone and the signal peptide
overlap and will be mutually exclusive in occupation. This sug-
gests that the signal peptide reaches its binding site by passing
through the region occupied by mycolactone and that the inhib-
itor directly prevents signal peptide-mediated opening of the
channel and subsequent removal of the plug.
These findings also have consequences for our understanding
of the dynamics of the translocon (Figure 5). The binding site for
ll
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the lateral gate opens through the tilting of helices H2 and H3
away from H7 and H8. It is hard to envisage mycolactone occu-
pying this binding pocket when Sec61a is in the process of trans-
location because the translocating translocon will be open, and
the nascent polypeptide chain is expected to occlude the myco-
lactone binding site. Indeed, this is supported by biochemical
assays showing that mycolactone does not affect cross-linking
of a substrate to Sec61a when added after translocation is initi-
ated bymicrosome addition (McKenna et al., 2016). Instead, my-
colactonewill bind while the translocon is idle. This suggests that
non-translocating Sec61a is in a dynamic equilibrium, transition-
ing between the closed state and a transient intermediate that re-
sembles the inhibitor-bound state. This conformational mobility
will be advantageous for the translocon because the plug helix
remains in place, keeping the channel of the translocon closed
to minimize ion leak, but movements in the lateral gate create
an opportunity for signal peptide binding and gating. The finding
that Sec62/63 stabilizes this intermediate to facilitate post-trans-
lational translocation supports this view. However, this interme-
diate is also susceptible to inhibition, with transient opening of
the lateral gate creating the inhibitor binding pocket, allowing
mycolactone to wedge open the lateral gate and block access
to the signal peptide binding site.
Translocation inhibitors with profoundly different chemical
structures show cross-competition and are affected by the
same resistance mutations (Van Puyenbroeck and Vermeire,
2018), suggesting that this mechanism is not restricted to myco-
lactone but common andwidely exploitable. Indeed, our findings
may also explain why the same resistance mutations affect the
efficacy of inhibitors as diverse in structure as cyclic peptides,
glycolipids, and polyketide lactones because they modulate for-
mation of their shared binding site. Translocation inhibitors have
been suggested as potential anti-cancer and anti-inflammatory
agents (Van Puyenbroeck and Vermeire, 2018) and would be ex-
pected to have powerful activity against enveloped viruses. This
structure not only yields new insight into the mechanism of the
translocon but also provides invaluable insight to guide future
rational drug design.STAR+METHODS
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index.php/Main_Page
UCSF MotionCor2 Zheng et al., 2017 https://emcore.ucsf.edu/ucsf-motioncor2
CTFFIND 4.1 Rohou and Grigorieff, 2015 https://grigoriefflab.umassmed.edu/
ctffind4
SIMPLE Elmlund and Elmlund, 2012 https://simplecryoem.com
ResMap Swint-Kruse and Brown, 2005 http://resmap.sourceforge.net
EPU 2.3 ThermoFisher Scientific N/A
Adobe Illustrator Adobe N/A
Xcalibur 4.2 Quan Browser Thermo Scientific N/A
Chromas Lite Technelysium
BLASTn NCBI https://blast.ncbi.nlm.nih.gov/Blast.cgi
Prism 8.2.1 GraphPad N/A
Excel 2016 Microsoft N/A
Powerpoint 2016 Microsoft N/A
ImageJ 1.52p NIH https://imagej.nih.gov/ij/
GROMACS 2019 Van Der Spoel et al., 2005 http://www.gromacs.org/
VMD 1.9 Humphrey et al., 1996 https://www.ks.uiuc.edu/Research/vmd/
MDAnalysis Michaud-Agrawal et al., 2011 https://www.mdanalysis.org/
Python https://www.python.org/
Matplotlib https://doi.org/10.5281/zenodo.2577644 https://matplotlib.org/
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REAGENT or RESOURCE SOURCE IDENTIFIER
PyMOL The PyMOL Molecular Graphics System,
Version 1.8 Schro¨dinger, LLC.
https://pymol.org/2/
Other
Sephacryl S-300 HR GE Healthcare Cat#17059910
Micrococcal nuclease New England Biolabs Cat#M0247S
Rabbit reticulocyte lysate, nuclease treated Promega Cat#L4960
Albumin,bovine serum, protease free ThermoFisher Scientific Cat#11461655
Graphene oxide dispersion Graphenea Cat#947-768-1
Quantifoil R 1.2/1.3 200 Mesh, copper Quantifoil Cat#Q2100CR1.3
4–20% TGX Mini-Protean precast gels BioRad Cat#4561903
Spectra broad-range protein markers Thermo Fisher Scientific Cat#266234
Simply Blue Thermo Fisher Scientific Cat#10432072
Immobilon-P PVDF membrane Thermo Fisher Scientific Cat#15750319
Immobilon Western chemiluminescent
substrate
Sigma Aldrich Cat# WBKLS
McCoy’s 5A (modified) Medium ThermoFisher Scientific Cat#11530646
Foetal Bovine Serum, heat inactivated, SA
origin
ThermoFisher Scientific Cat#11550356
Superscript IV Life Technologies Cat# 18090050
GoTaq G2 Green Mastermix Promega Cat# M7822
Dulbecco’s Modified Eagle’s Medium - high
glucose
Sigma Aldrich Cat#D6429
Fugene 6 Promega Cat#E2691
Protease inhibitor cocktail Sigma Aldrich Cat#P8340
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Lead Contact
Further information and requests for resources and reagents should be directed to and will be fulfilled by the Lead Contact, Rachel
Simmonds rachel.simmonds@surrey.ac.uk
Materials Availability
All unique/stable reagents generated in this study (plasmids containing mutant human Sec61a and mycolactone-resistant cell lines)
are available from the Lead Contact without restriction.
Data and Code Availability
The electron microscopy datasets generated during this study, in the form of maps, are available at the electron microscopy data
bank (EMD-11064). Themodel for the Sec transloconwithmycolactone bound, generated during this study, is available at the protein
data bank PDB: (6Z3T). Other data associatedwith themanuscript is available at https://data.mendeley.com/datasets/cc92fyz9sv/1.
EXPERIMENTAL MODEL AND SUBJECT DETAIL
Cell lines
The male human colorectal cancer cell line HCT-116 (ATCC CCL-247) was maintained in McCoy’s 5A (modified) medium supple-
mented with 10% fetal bovine serum (FBS) and 1x penicillin-streptomycin (both Thermo Fisher Scientific). TRex-293 cells, derived
from the female human embryonic kidney line HEK293, were maintained in high glucose DMEM, supplemented with 10% FBS. Cells
were routinely cultured at 37C and 5% CO2. We do not routinely authenticate our cell lines.e3 Molecular Cell 79, 406–415.e1–e7, August 6, 2020
ll
OPEN ACCESSArticleMETHOD DETAILS
Mycolactone
We used synthetic mycolactone A/B, kindly provided by Prof Yoshito Kishi (Harvard University) (Song et al., 2002) for all of the ex-
periments described in this manuscript. Mycolactone A/B is a 3:2 rapidly equilibrating mixture of Z-D4’,5
0
(A) and E-D4’,5
0
(B) geometric
isomers at the second double bond in the southern fatty acid tail. Since the two isomers cannot be separated in light, as they rapidly
re-equilibrate to the 3:2 ratio, we refer to them as mycolactone. Mycolactone was provided in ethyl-acetate, dried down under nitro-
gen and resuspended in DMSO at 0.5 mg/ml. Aliquots are protected from light and stored at 80C.
For selection of stably transfected TRex-293 cells to derive overexpressing mycolactone resistance mutations, we used synthetic
mycolactone A/B as a mixture of epimers at C120, kindly provided by Dr Nicolas Blanchard (Saint-Auret et al., 2017a, 2017b) (French
National Centre for Scientific Research), which is available in the greater amounts needed for cells under selection. However, tests
performed with stable clones used mycolactone A/B (Song et al., 2002).
Purification of ribosome-translocon complexes
Ribosome-associated Sec61 complexes, known as ribosome-translocon complexes or RTCs, were prepared largely as described
(Voorhees et al., 2014). Briefly, rough microsomal membranes (CPMM) were prepared from dog pancreas as described (Walter and
Blobel, 1983) and stored at 80C in 50 mM triethanolamine (pH 7.5), 250 mM sucrose, 1 mM DTT. Aliquots were incubated with
1 mM CaCl2 and 150 U/ml micrococcal nuclease for 7 min at room temperature. The reaction was stopped by addition of 2 mM
EGTA and microsomes were flash-frozen in 50 ml aliquots. Mycolactone (1 mg/ml) was prepared by dilution in 0.1% (w/v) BSA
from a concentrated stock. Control samples contained 0.1% (v/v) DMSO in BSA. Microsomes were thawed on ice and mycolactone
was added to 200 ng/ml (269.2 nM). After gentle mixing, samples were incubated on ice for 30 min. Microsomes were solubilised by
incubation for 10 min on ice with an equal volume of 100 mM HEPES pH 7.5, 800 mM KOAc, 20 mM MgOAc, 3.5% (w/v) digitonin,
2 mMDTT. Samples were centrifuged at 20,000 x g for 15min at 4C. An aliquot of supernatant (5ml) was removed for LC-MS analysis
and the rest was applied to a 1mL Sephacryl-300 column pre-equilibrated with ice cold column buffer (50mMHEPES pH7.5, 200mM
KOAc, 10mMMgOAc, 0.25% (w/v) digitonin, 1mMDTT). Samples were eluted at 4C in column buffer and collected in approximately
100 ml fractions. Absorbance at 260 nm was estimated using a Nanodrop (Thermo Fisher) and the initial peak eluting fractions were
pooled. Samples were re-centrifuged at 20,000 x g for 15 min at 4C and processed immediately for electron cryo-microscopy.
In vitro translation/translocation assays
In vitro translation/translocation assays were performed as previously described (Hall et al., 2014). Briefly, mycolactonewas added to
micronuclease-treated canine pancreatic microsomes and incubated on ice for 20 min in the dark. In vitro translation reactions were
carried out in a 25 ml volume using nuclease-free rabbit reticulocyte lysates (Promega) according to manufacturer’s instructions, with
0.5 mg prepro-a Factor mRNA and 35-S methionine. Microsomal membranes, when present, made up 10% of the final volume of the
reaction mix. Samples were incubated for 30 min at 30C and the reaction was stopped with the addition of an equal volume of 2x
Laemmli sample buffer. Proteins were separated by SDS-PAGE on 4%–15% acrylamide gels, fixed, stained, and dried, then visu-
alized with a Typhoon Phosphorimager (GE Healthcare).
Liquid chromatography mass spectrometry
Liquid chromatography mass spectrometry (LC-MS) was performed on a Thermo Scientific Ultimate3000 UHPLC system equipped
with a binary solvent manager, column manager, and autosampler, coupled to a Thermo Orbitrap Q-Exactive Plus mass spectrom-
eter operating with the standard electrospray ionization interface and the following conditions: spray voltage 4 kV, capillary temp.
375C, sheath gas 60 psi, aux gas 20 psi, S lens RF level 100%, resolution 70,000, divert valve schedule (to divert sample buffer com-
ponents away from MS): 0-2.3 min, waste; 2.3-3.0 min, MS; 3.0-5.0 min, waste. Liquid chromatography conditions were as follows:
injection volume 10 mL; column: Phenomenex Luna Omega (C18 porous silica, 2.1 3 50 mm, 5 mm particle size, 100 A˚ pore size);
column temp. 25C, flow rate 0.5 mL min-1; mobile phase Solvent A: aqueous ammonium acetate (10mM), pH 6.9; Solvent B: aceto-
nitrile; gradient 0-1 min, 5% B; 1-2 min, 5%–90% B; 2-3.5 min, 90% B; 3.5-4.5 min,90%–5% B; 4.5-5 min, 5% B; autosampler
temp. 10C.
The identity and LC-MS retention time of pure mycolactone A/B bound to microsomes was confirmed by both accurate mass and
MS/MS of the [M+Na]+ ion which showed the same fragmentation pattern of sodium adducts reported previously (Hong et al., 2003)
(core + northern chain m/z 429; southern fatty acid m/z 359).
For mycolactone quantification, a set of standards for an LC-MS calibration curve were set up using synthetic mycolactone A/B
dissolved into acetonitrile/water (1:1). The standards were analyzed by LC-MS once before each repeat of experimental samples.
Extracted ion chromatograms (EIC) for mass range 765.4721 – 765.5103 (mycolactone A/B [M+Na]+) were produced using Thermo
Scientific Xcalibur 4.2 Quan Browser. Peak areas were first generated automatically for retention time range 2.68 min with window
36 s (2.38 – 2.98 min), ICIS peak integration using smoothing points 7, baseline window 40, area noise factor 5, peak noise factor 10.
This was followed by manual adjustment of the integration to include the entire EIC peak.
Experimental samples were: freshly prepared stocks of mycolactone (13.46 mM; 10 mg/ml) in 0.1% (w/v) BSA diluted 1:50 or 1:500
in acetonitrile/water (1:1), total extract from microsomes incubated with or without mycolactone diluted 1:10 in acetonitrile/waterMolecular Cell 79, 406–415.e1–e7, August 6, 2020 e4
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tween. Mycolactone concentrations were determined relative to the calibration curve.
SDS-PAGE and immunoblotting
Aliquots of column eluted fractions were separated by SDS-PAGE on 4%–20%acrylamide gradient gels (Bio-Rad) alongside Spectra
broad-range protein markers (Thermo Fisher Scientific). Proteins were stained with Simply Blue (Thermo Fisher Scientific) or blotted
onto PVDFmembranes. After transfer, blots were fixedwith 5% acetic acid and blocked with 5%milk. Primary antibodies usedwere:
mouse monoclonal anti-Sec61a; rabbit polyclonal anti-Sec61b (Kind gift from the Dobberstein lab) (Kelkar and Dobberstein, 2009);
rabbit polyclonal anti-ribosomal protein S6 and mouse monoclonal anti-ribophorin 2 (Santa Cruz Biotechnology, sc-166421).
Secondary antibodies were ECLMouse IgG, HRP-linked (GE Healthcare, NXA931) and ECL Rabbit IgG, HRP-linked (GE Healthcare,
NA934). Western blots were incubated with Immobilion Chemiluminescent HRP substrate and imaged using a Vilber Fusion FX im-
aging system. Images presented here were inverted using ImageJ v.1.52p.
Grid preparation and data acquisition
Carbon-coated holey grids (Quantifoil, R1.2/1.3, 200 mesh) were used for the preparation of graphene-oxide grids. The grids were
plasma-cleaned using a Quorum device at 50 mA for 60 s. For each grid, 3 mL of 0.2 mg/ml graphene oxide dispersion (Graphenea)
was applied on the carbon surface, manually blotted, and allowed to dry overnight.
A 4 mL sample with an absorbance of 10 at 260nmwas applied on the surface of each grid and vitrified by plunge-freezing in liquid
ethane using a Vitrobot (FEI) with an incubation time of 15 s, a blotting time of 5 s and a blotting force of 15 at 4C.
Data were collected manually using the acquisition software EPU on a Titan Krios transmission electron microscope (FEI) at a de-
focus range between 1 and 2.5 mm. All data were recorded on a K2 detector under low dose conditions with a nominal pixel size of
0.822 A˚/pixel on the object scale. A total of 5062 and 3833 micrographs were collected for RTCs with and without mycolactone,
respectively. Eachmicrograph experienced a total exposure of49 electrons per A2 fractionated into 32 frames. Foil holes containing
the thinnest regions of ice and darkest edges were manually selected as they mostly contained single layer graphene oxide and
showed higher signal-to-noise ratio.
Image processing
Original movie frames were motion corrected and combined using MotionCor2 (Zheng et al., 2017). The contrast transfer function
parameters were estimated via CTFFIND4.1 (Rohou and Grigorieff, 2015). All micrographs were screened manually for graphene ox-
ide and ice quality. Particles were picked automatically with SIMPLE (Elmlund and Elmlund, 2012). All classifications and refinements
were performed using Relion3 (Scheres, 2012; Zivanov et al., 2018). After reference-free 2D classification, particles (76,650 for RTCs
withmycolactone, 35,366 for the control dataset) were subjected to an extensive 3D classification into 10 classes after an initial round
of refinement.
The main differences between the three-dimensional classes was the absence or presence of eEF2, while most ribosomes con-
tained tRNA in P/E-state or E-state. Two main classes were selected, which included ribosomes with eEF2 (32,456 particles in the
presence of mycolactone, 8,607 in the control dataset) and without eEF2 (18,365 particles with mycolactone, 16,245 without). Com-
parison of these ribosome states with those seen by Voorhees et al. (2014), who used a similar protocol for purification of ribosome-
translocon complexes, revealed similarities and differences. Voorhees observed 13% active ribosomes (with A/P and P/E-site
tRNAs), 65%without tRNA but with eEF2 and 22% empty (Voorhees et al., 2014). The Voorhees et al. (2014) data share with our find-
ings the presence of a majority of idle ribosomes and the surprising presence of a large fraction containing elongation factor eEF2.
The major difference in ribosome conformation when compared with Voorhees is the presence of E or P/E site tRNAs in our RTCs,
while Voorhees et al. (2014) observed predominantly tRNA-free ribosomes. We are not sure of the reasons for the differences here,
but they might be due to different sources of microsomes (porcine versus canine) or subtle differences in the preparation procedure
or time taken for purification.
For each state, 60S-Sec61 masked refinement, followed by particle subtraction of the ribosome core, were carried out. The sub-
tracted particles were used for focused 3D classification with a mask applied around Sec61. The best classes were selected and
subjected to 60S-Sec61 masked 3D refinement after particle polishing and CTF refinement. Particles from the two reconstructions
obtained were combined, as no differences were observed in the conformation of the translocon, followed by a final 60S-Sec61
masked refinement. In the case of the control dataset, the same pipeline was used, without focused classification. All final recon-
structions were subjected to post processing using a wide soft edge mask. This resulted in final resolutions of 2.63A˚ and 2.85A˚, ac-
cording to the FSC 0.143 criterion following the Relion gold-standard refinement (Scheres and Chen, 2012). Local resolution at the
translocon was estimated using ResMap (Swint-Kruse and Brown, 2005). For better visualization and interpretation of the Sec den-
sity, and due to the heterogenous resolution across the translocon, the map used for model building was lowpass-filtered to 4A˚.
Homology modeling and refinement of atomic models
The structure of Sec61 was built using the structures of the primed state (RCSB code 3J7Q) and that of the signal peptide-engaged
state (RCSB code 3JC2) as reference models. The model was built in COOT (Emsley and Cowtan, 2004) and refined using Phenix
(Adams et al., 2010) using Ramachandran and secondary structure restraints.e5 Molecular Cell 79, 406–415.e1–e7, August 6, 2020
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The final model derived from electron cryo-microscopy was used as the starting point for molecular dynamics simulations. The
original conformation had mycolactone docked with the southern chain projecting toward the lipid phase while in the reversed
conformation, the southern chain projected toward the translocon. The presumptive active form, the E-D4’5’ isomer, was selected
for the simulations. The parameters for mycolactone were taken from (Lo´pez et al., 2018), who developed them using the General
Amber force field (GAFF) (Wang et al., 2004) in combination with the restrained electrostatic potential (RESP) approach (Bayley
et al., 1993) employed for optimization of partial charges. The Amber 99SB-ILDN force field (Lindorff-Larsen et al., 2010) was adopted
for Sec61 in conjunction with the TIP3Pwater model (Jorgensen et al., 1983). The POPC lipids were representedwith the Slipids force
field (J€ambeck and Lyubartsev, 2012a, 2012b, 2013).
The Sec61/mycolactone complex was first oriented with the translocon pore axis aligned coincident with the membrane normal of
a pre-equilibrated POPC lipid bilayer containing 512 lipids, ensuring that the transmembrane helices of the Sec61a overlap with the
hydrophobic region of the lipid membrane. Heavy atoms were position-restrained with a harmonic potential and a strong force con-
stant of 105 kJmol-1 nm-2 and the inflateGRO tool (Kandt et al., 2007) was executed to rescale the lipid atom coordinates by a factor of
four. A series of 25 iterations of shrinking and energy minimizing was performed until the POPC area per lipid was 71 A˚2, a little above
the equilibrium area per lipid of 65.8 A˚2 (Tieleman et al., 1998). The system was subsequently solvated and any water molecules in-
serted in the lipid phase were deleted. NaCl was added to neutralize the system and to provide a physiological ion concentration of
0.15 M.
Molecular dynamics simulations were performed using the GROMACS software package, version 2019 (Van Der Spoel et al.,
2005). Initially, the system was energy minimized with the steepest descent algorithm until the maximum force did not exceed
100 kJ mol-1 nm-1. A short equilibration run in the NVT ensemble was carried out for 5 ns and the temperature was stabilized at
310 K with the velocity-rescale thermostat (Bussi et al., 2007) and a coupling constant of 0.1 ps. An additional equilibration step
was performed subsequently in the NPT ensemble for 10 ns. In this case, the temperature was maintained at 310 K using the
Nose´–Hoover thermostat (Hoover, 1985; Nose, 1983a, 1988) and a time constant of 0.5 ps, while the target pressure of 1 bar was
reached using the Parrinello-Rahman barostat (Nose and Klein, 1983; Parrinello and Rahman, 1981) and a semi-isotropic coupling
with a time constant of 5 ps. For the MD production runs, the protein backbone atoms were position-restrained by applying a soft
harmonic potential with a force constant of 500 kJ mol-1 nm-2, in order to ensure that the Sec61 state obtained from electron micro-
scopywould bemaintained despite the absence of the ribosome during simulations. Periodic boundary conditions were applied in all
three dimensions. The hydrogen-containing bonds were constrained using the LINCS algorithm (Hess, 2008). Neighbor searching,
Lennard-Jones interactions and real-space Coulomb interactions were cut off at 10 A˚. A dispersion correction was applied to energy
and pressure to account for truncation of Lennard-Jones interactions. The particle-mesh Ewald summation was adopted for treat-
ment of reciprocal-space electrostatic interactions with a cubic interpolation and a grid spacing of 1.2 A˚. The time step was 2 fs and
the leap-frog algorithmwas selected for integration of the equations of motion. Coordinates were saved every 10 ps. Three repeats of
100 ns-long MD runs were subsequently performed for each system, amounting to a total simulation time of 600 ns.
To investigate the effect of mutations on mycolactone stability, three mutant systems were generated (S71F, G80W and S82F)
using the mutagenesis tool of PyMOL (The PyMOL Molecular Graphics System, Version 1.8 Schro¨dinger, LLC.). The starting config-
uration was again the model derived from electron cryo-microscopy, with mycolactone docked in the original conformation. For sys-
tem setup, equilibration and production runs, the same parameters and procedure as described above were adopted, with the
exception that for production runs, position restraints were applied only to the heavy atoms of the Sec61g subunit and the transmem-
brane helices H6-H10 of Sec61a to allow the rest of Sec61a to adapt to conformational changes caused by the presence of the mu-
tation. For each mutant system and the WT, three 100 ns-long production runs were performed, resulting in a total simulation time
of 1.2 ms.
The VMD software (Humphrey et al., 1996) was used for visualization and the MDAnalysis package (Michaud-Agrawal et al., 2011)
for trajectory analysis.
Forward genetic screen and viability assays
The forward genetic screen in DNA damage repair-resistant HCT-116 cells was performed as described (Junne et al., 2015; Ogbechi
et al., 2018). The mutagen was ethyl methane sulphonate and selection was with 10 ng/ml (13.5 nM) mycolactone A/B. The cDNA for
SEC61A1was sequenced in resistant clones by RT-PCR. Total RNA (1 mg) was reverse transcribed using Superscript IV reverse tran-
scriptase (Life Technologies) according to the manufacturer’s instructions. The coding regions of SEC61A1 were amplified in four
overlapping fragments using primers Sec61A1_frag1F/ Sec61A1_frag1R, Sec61A1_frag2F/ Sec61A1_frag2R, Sec61A1_frag3F/ Se-
c61A1_frag3R, Sec61A1_frag4F/ Sec61A1_frag4R with GoTaq G2 Green Mastermix (Promega). In some cases, confirmation of mu-
tations used an additional fifth fragment using primers Sec61A1_frag5F/ Sec61A1_frag5R. The cycling conditions were 95C for 2min,
35x cycles of 95C for 30 s, 58C for 30 s and 72C for 1min, then 5min at 72C. After clean-up, 70ng of each PCR product along with the
corresponding forward primer were sent for Sanger sequencing using the Eurofins Mix2Seq service. Returned sequences, covering
the entire coding region were analyzed using Chromas and BLASTn to identify the mutations. No homozygous mutations were iden-
tified. The parental cells and all resistant cell lines were heterozygous for a silent C/T transition in Thr445 (ACC/ACT). Almost all clones
analyzed showed heterozygous mutations of single alleles. One exception was Hct7 which showed both Q127K and S82Y. Hct30
carried R66K and potentially P140T (as yet unconfirmed).Molecular Cell 79, 406–415.e1–e7, August 6, 2020 e6
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(CT8: kind gift of Jack Taunton), or ipomoeassin F (Cao et al., 2007) (kind gift of Wei Shi) for 5 days. Then resazurin was added to
a final concentration of 0.01 mg/ml. After 4 h further incubation, viability was measured as emission at 620 nm at excitation
580 nm using a BMG Fluostar Optima Microplate Reader. Data are expressed as a viability index, representing the relative signal
compared to the negative control (DMSO-treated cells).
Generation of mycolactone resistant cell lines
Synthetic C-terminal Flag-tagged Sec61A1 genes containing the mutations S71F, G80W and S85Y were generated (Thermo Fisher
GeneArt) and cloned into the pNLF1-C vector (Promega), replacing the nanoluciferase insert. The plasmidwas digestedwithMluI and
2 mg transfected into TRex-293 cells (Thermo Fisher) with Fugene (Promega) according to themanufacturer’s instructions. Cells were
selected for oneweek in the presence of 10 ng/ml (13.5 nM)mycolactone epimers (kind gift fromDr Nicolas Blanchard, CRNS France)
(Saint-Auret et al., 2017a, 2017b) and then for 1 weekwith 600 mg/ml hygromycin (Thermo Fisher). Expression of themutant genewas
confirmed by immunoblotting, and/or immunofluorescence, for the Flag tag. Single clones were selected for analysis.
Immunofluorescence
Cells were transiently transfected with plasmids containing mutant Sec61 genes, incubated overnight, then seeded onto coverslips.
After a further 24 hr incubation, cells were fixed with 4% paraformaldehyde in PBS and blocked with 1% BSA/PBS. Coverslips were
incubated with anti-Flag antibody followed by Alex488 conjugated anti-rabbit antibody, then counterstained with DAPI.
Microsome preparation
Crude rough microsomes were prepared from cells by the method described in Chitwood et al. (2018) with minor variations. Briefly,
wild-type TRex-293 cells and those clones overexpressing Sec61amutants were grown to 70%–90% confluency on eight 500 cm2
plates, collected in ice-cold PBS using cell lifters (Costar), centrifuged at 500 x g for 5 min at 4C, and washed twice in ice-cold PBS.
The cell pellet was resuspended in 3 pellet volumes of ice-cold buffer (10 mMHEPES, pH 7.4, 250 mM sucrose, 2 mMMgOAc). Cells
were lysed in the cold (4C) by 25 passes through a 25-gauge needle using a 10mL syringe. The lysates were centrifuged at 3,800 x g
for 30 min at 4C. The supernatant was centrifuged at 75,000 x g for 1 h at 4C in an SW55Ti rotor (Beckman Coulter). The membrane
pellet was resuspended inmicrosome buffer (10mMHEPES, pH 7.4, 250mMsucrose, 1mMDTT). Aliquots were taken at each stage
for analysis by immunoblotting and assessment of absorbance at 260 nm. RTCs were isolated from cell derived microsomal prep-
arations as described above for CPMM.
Figure preparation
Figures were prepared using the programs Chimera (Goddard et al., 2007), ChimeraX (Goddard et al., 2018) and GraphPad Prism
versions 7.0 or 8.2.1 (GraphPad Software).
QUANTIFICATION AND STATISTICAL ANALYSIS
For mycolactone quantification by LC-MS, the calibration curve was established using the mean of the three repeat runs and the
slope and intercept were calculated (Microsoft Excel 2016) for interpolation of mycolactone concentrations in samples. In order to
compare TRex-293 cells to those overexpressing Sec61amutants, the absorbance at 260 nm was used to estimate the concentra-
tion of RTCs in the recovered samples, using a mMextinction coefficient of 60.8 (Collins andGilmore, 1991), for the 80S ribosome. The
ratio of mycolactone:RTCs was normalized to wild-type cells. Alternatively, the pixel intensity of the Sec61a band from immunoblots
of equal volumes of recovered RTCs (measured using ImageJ v.1.52p) was used to estimate the normalized relative ratio. Here, the
individual data from the triplicatemeasurements from a single run is shown. Since the endogenous Sec61awas not depleted from the
cells prior to the analysis, all preparations contain some wild-type Sec61a.
For quantification of cell viability, each biological repeat was performed in triplicate. The data were normalized to the mean of the
absorbance at 620 nm for DMSO-treated cells (solvent control). When combining the data from independent biological repeats, the
mean of each normalized technical triplicate was taken. The IC50 for wild-type cells was calculated using log(inhibitor) versus
response – variable slope (four parameter) usingGraphpad v. 8.2.1. No slopeswere fitted to the resistant clones, as the fit was ambig-
uous, and no statistical comparison was performed. In the figure legends, n is the number of biological repeats (independent
experiments).e7 Molecular Cell 79, 406–415.e1–e7, August 6, 2020
